Pratik Shah
CIK: 0001580787
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jun 24, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30K shares- - Jan 2, 2026DSGN
Design Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
750K shares- - Dec 9, 2025DSGN
Design Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
525K shares- - Dec 9, 2025DSGN
Design Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
525K shares- - Nov 12, 2025SPRY
ARS Pharmaceuticals, Inc.
Gift(G)Indirect250K shares- - Nov 12, 2025SPRY
ARS Pharmaceuticals, Inc.
Gift(G)Indirect100K shares- - Jun 25, 2025SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30K shares- - Jan 2, 2025DSGN
Design Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
600K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 |  SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| Jan 2, 2026 |  DSGN Design Therapeutics, Inc. | Award(A) Stock option (right to buy) | 750,000 | - | - | Direct |
| Dec 9, 2025 | DSGN Design Therapeutics, Inc. | Award(A) Stock option (right to buy) | 525,000 | - | - | Direct |
| Dec 9, 2025 | DSGN Design Therapeutics, Inc. | Award(A) Stock option (right to buy) | 525,000 | - | - | Direct |
| Nov 12, 2025 | SPRY ARS Pharmaceuticals, Inc. | Gift(G) | 250,000 | - | - | Indirect |
| Nov 12, 2025 | SPRY ARS Pharmaceuticals, Inc. | Gift(G) | 100,000 | - | - | Indirect |
| Jun 25, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| Jan 2, 2025 | DSGN Design Therapeutics, Inc. | Award(A) Stock option (right to buy) | 600,000 | - | - | Direct |
1-8 of 8 transactions
About Shah Pratik
Shah Pratik (SEC CIK 0001580787) files insider reports with the SEC as Director of ARS Pharmaceuticals, Inc. (SPRY) and President, CEO and Chairperson of Design Therapeutics, Inc. (DSGN).
Signal8 holds 6 ownership filings by Shah Pratik, all Form 4s, filed between Jan 6, 2025 and Jun 26, 2026. Those filings report 8 transactions, from Jan 2, 2025 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Shah Pratik's filings is in SAN DIEGO, CA.
Recent filings by Shah Pratik
- Jun 24, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
- Jan 2, 2026: Grant or award of DSGN derivative securities (Form 4, code A).
- Dec 9, 2025: Grants or awards of DSGN derivative securities (2 lines, Form 4, code A).
- Nov 12, 2025: Gifts of SPRY shares (2 lines, Form 4, code G).
- Jun 25, 2025: Grant or award of SPRY derivative securities (Form 4, code A).
Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)
- Casale Donn, President and CEO
- Smith Margaret Ekins, Chief Commercial Officer
- RA CAPITAL MANAGEMENT, L.P., Director
- Dadoo Rajeev, Director
- Kelly Michael, Director
- Islam Saqib, Director